Rivaroxaban Intermediate CAS 446292-07-5 Ubunyulu ≥98.0% (HPLC) Factory
Ubonelelo loMvelisi iRivaroxaban eNxulumeneyo nabaPhakathi:
(S)-(+)-Glycidyl Phthalimide CAS 161596-47-0
4-(4-Aminophenyl)morpholin-3-enye CAS 438056-69-0
Rivaroxaban Intermediate CAS 446292-07-5
I-5-Chlorothiophene-2-Carboxylic Acid CAS 24065-33-6
5-Chlorothiophene-2-Carbonyl Chloride CAS 42518-98-9
Rivaroxaban API CAS 366789-02-8
Igama leMchiza | 2-[(2R)-2-Hydroxy-3-[[4-(3-oxo-4-morpholinyl)phenyl]amino]propyl]-1H-isoindole-1,3(2H)-dione |
Izithethantonye | Rivaroxaban Intermediate |
Inombolo yeCAS | 446292-07-5 |
Inombolo yeCAT | RF-PI130 |
Ubume beStokhwe | Kwi-Stock, iMveliso yeMveliso ukuya kumakhulu eeKilogram |
Ifomula yeemolekyuli | I-C21H21N3O5 |
Ubunzima beMolekyuli | 395.41 |
Uphawu | Ruifu Chemical |
Into | Iinkcukacha |
Imbonakalo | Umgubo oMhlophe |
Ubunyulu / Indlela yokuHlalutya | ≥98.0% (HPLC) |
Indawo yokunyibilika | 210.0℃~215.0℃ |
Nakuphi na Ukungacoceki komntu | ≤1.0% |
Ilahleko ekomisweni | ≤0.50% |
Intsalela kwi-Ignition | ≤0.10% |
Umgangatho woVavanyo | Umgangatho woShishino |
Ukusetyenziswa | Rivaroxaban (CAS: 366789-02-8) Phakathi |
Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, igubu lekhadibhodi, 25kg/Igubu, okanye ngokwemfuno yomthengi.
Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ekukhanyeni, ukufuma kunye nokuhlaselwa zizinambuzane.
I-Shanghai Ruifu Chemical Co., Ltd. ngumenzi okhokelayo kunye nomthengisi we-2-[(2R)-2-Hydroxy-3-[[4-(3-oxo-4-morpholinyl)phenyl]amino]propyl]-1H- i-isoindole-1,3 (2H) -dione (CAS: 446292-07-5) enomgangatho ophezulu.Yinto ephakathi ngokuqhelekileyo kwi-synthesis yeRivaroxaban (CAS: 366789-02-8).I-Rivaroxaban yinto ecocekileyo (S) -enantiomer.I-Rivaroxaban (i-BAY 59-7939) yinto yomlomo, ngokuthe ngqo kwi-Xa inhibitor ekuphuhlisweni kweklinikhi yokukhusela kunye nokunyangwa kwe-venous thromboembolism (VTE).I-Rivaroxaban iyeza le-antithrombotic kwaye yaphuhliswa ngokubambisana phakathi kwe-German Bayer Pharmaceuticals kunye nenkampani yaseMelika Johnson.